In atherosclerosis‐prone mouse models, the combination of alirocumab (a PCSK9 monoclonal antibody) with statins demonstrated neuroprotective potential by stabilizing atherosclerotic plaques and mitigating vascular endothelial damage through inhibition of inflammatory cytokines such as IL‐6 and TNF‐α, thereby indirectly preserving neurological function [118]. Here, PCSK9 is linked to atherosclerosis.